Association of MTHFR, MTR, and MTRR polymorphisms with Parkinson's disease among ethnic Chinese in Taiwan

Clinica Chimica Acta

Volumn 412, Issue 3-4, 2011, Pages 332-338

  Fong, Chin Shih ^a,b   Shyu, Hann Yeh ^c   Shieh, Jia Ching ^d   Fu, Yi Ping ^e   Chin, Ting Yu ^f   Wang, Hsiao Wei ^d,g   Cheng, Chun Wen ^d,g  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c TAOYUAN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^f CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

^g CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Genetic polymorphism; MTHFR; MTR; MTRR; Parkinson's disease

Indexed keywords

5 METHYLENETETRAHYDROFOLATE HOMOCYSTEINE METHYLTRANSFERASE REDUCTASE; FOLIC ACID; GENOMIC DNA; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; METHYLENETETRAHYDROFOLATE HOMOCYSTEINE METHYLTRANSFERASE; METHYLTRANSFERASE; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHINESE; CONTROLLED STUDY; FEMALE; FOLATE METABOLISM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MOUTH MUCOSA; MUCOSA CELL; MUTATIONAL ANALYSIS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TAIWAN;

5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; FERREDOXIN-NADP REDUCTASE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HOSPITALS; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, GENETIC; TAIWAN;

EID: 78650235220     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.11.004     Document Type: Article

References (46)

1. dos Santos E.F., Busanello E.N., Miglioranza A., Zanatta A., Barchak A.G., Vargas C.R., et al. Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease. Metab Brain Dis 2009, 24:257-269.
2. Duan W., Ladenheim B., Cutler R.G., Kruman I.I., Cadet J.L., Mattson M.P. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002, 80:101-110.
3. Imamura K., Takeshima T., Nakaso K., Nakashima K. Homocysteine is toxic for dopaminergic neurons in primary mesencephalic culture. NeuroReport 2007, 18:1319-1322.
4. Chandra G., Gangopadhyay P.K., Senthil Kumar K.S., Mohanakumar K.P. Acute intranigral homocysteine administration produces stereotypic behavioral changes and striatal dopamine depletion in Sprague-Dawley rats. Brain Res 2006, 1075:81-92.
5. Tjiattas L., Ortiz D.O., Dhivant S., Mitton K., Rogers E., Shea T.B. Folate deficiency and homocysteine induce toxicity in cultured dorsal root ganglion neurons via cytosolic calcium accumulation. Aging Cell 2004, 3:71-76.
6. Zoccolella S., Martino D., Defazio G., Lamberti P., Livrea P. Hyperhomocysteinemia in movement disorders: current evidence and hypotheses. Curr Vasc Pharmacol 2006, 4:237-243.
7. Rogers J.D., Sanchez-Saffon A., Frol A.B., Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003, 60:59-64.
8. Botto N., Andreassi M.G., Manfredi S., Masetti S., Cocci F., Colombo M.G., et al. Genetic polymorphisms in folate and homocysteine metabolism as risk factors for DNA damage. Eur J Hum Genet 2003, 11:671-678.
9. Hazra A., Kraft P., Lazarus R., Chen C., Chanock S.J., Jacques P., et al. Genome-wide significant predictors of metabolites in the one-carbon metabolism pathway. Hum Mol Genet 2009, 18:4677-4687.
10. Tanaka T., Scheet P., Giusti B., Bandinelli S., Piras M.G., Usala G., et al. Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. Am J Hum Genet 2009, 84:477-482.
11. Bagley P.J., Selhub J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci USA 1998, 95:13217-13220.
12. Pejchal R., Campbell E., Guenther B.D., Lennon B.W., Matthews R.G., Ludwig M.L. Structural perturbations in the Ala→Val polymorphism of methylenetetrahydrofolate reductase: how binding of folates may protect against inactivation. Biochemistry 2006, 45:4808-4818.
13. Watkins D., Ru M., Hwang H.Y., Kim C.D., Murray A., Philip N.S., et al. Hyperhomocysteinemia due to methionine synthase deficiency, cblG: structure of the MTR gene, genotype diversity, and recognition of a common mutation, P1173L. Am J Hum Genet 2002, 71:143-153.
14. Laraqui A., Allami A., Carrie A., Coiffard A.S., Benkouka F., Benjouad A., et al. Relation between plasma homocysteine, gene polymorphisms of homocysteine metabolism-related enzymes, and angiographically proven coronary artery disease. Eur J Intern Med 2007, 18:474-483.
15. Religa D., Czyzewski K., Styczynska M., Peplonska B., Lokk J., Chodakowska-Zebrowska M., et al. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. Neurosci Lett 2006, 404:56-60.
16. Ohnami S., Sato Y., Yoshimura K., Ohnami S., Sakamoto H., Aoki K., et al. His595Tyr polymorphism in the methionine synthase reductase (MTRR) gene is associated with pancreatic cancer risk. Gastroenterology 2008, 135:477-488.
17. Shaw G.M., Lu W., Zhu H., Yang W., Briggs F.B., Carmichael S.L., et al. 118 SNPs of folate-related genes and risks of spina bifida and conotruncal heart defects. BMC Med Genet 2009, 10:49.
18. Almeida O.P., Flicker L., Lautenschlager N.T., Leedman P., Vasikaran S., van Bockxmeer F.M. Contribution of the MTHFR gene to the causal pathway for depression, anxiety and cognitive impairment in later life. Neurobiol Aging 2005, 26:251-257.
19. Cascalheira J.F., Joao S.S., Pinhancos S.S., Castro R., Palmeira M., Almeida S., et al. Serum homocysteine: interplay with other circulating and genetic factors in association to Alzheimer's type dementia. Clin Biochem 2009, 42:783-790.
20. Levin J., Botzel K., Giese A., Vogeser M., Lorenzl S. Elevated levels of methylmalonate and homocysteine in parkinson's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis. Dement Geriatr Cogn Disord 2010, 29:553-559.
21. Van Dam F., Van Gool W.A. Hyperhomocysteinemia and Alzheimer's disease: a systematic review. Arch Gerontol Geriatr 2009, 48:425-430.
22. Caccamo D., Gorgone G., Curro M., Parisi G., Di Iorio W., Menichetti C., et al. Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients. Neuromolecular Med 2007, 9:249-254.
23. Klerk M., Lievers K.J., Kluijtmans L.A., Blom H.J., den Heijer M., Schouten E.G., et al. The 2756A>G variant in the gene encoding methionine synthase: its relation with plasma homocysteine levels and risk of coronary heart disease in a Dutch case-control study. Thromb Res 2003, 110:87-91.
24. Laraqui A., Allami A., Carrie A., Coiffard A.S., Benkouka F., Benjouad A., et al. Influence of methionine synthase (A2756G) and methionine synthase reductase (A66G) polymorphisms on plasma homocysteine levels and relation to risk of coronary artery disease. Acta Cardiol 2006, 61:51-61.
25. Brown K.S., Kluijtmans L.A., Young I.S., Murray L., McMaster D., Woodside J.V. The 5, 10-methylenetetrahydrofolate reductase C677T polymorphism interacts with smoking to increase homocysteine. Atherosclerosis 2004, 174:315-322.
26. Husemoen L.L., Thomsen T.F., Fenger M., Jorgensen T. Effect of lifestyle factors on plasma total homocysteine concentrations in relation to MTHFR(C677T) genotype. Inter99 (7). Eur J Clin Nutr 2004, 58:1142-1150.
27. Yuan R.Y., Sheu J.J., Yu J.M., Hu C.J., Tseng I.J., Ho C.S., et al. Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients. J Neurol Sci 2009, 287:64-68.
28. Lin J.J., Yueh K.C., Liu C.S., Liu J.T., Lin S.Z. 5, 10-methylenetetrahydrofolate reductase C677T gene polymorphism can influence age at onset of Parkinson's disease. Acta Neurol Taiwan 2007, 16:150-157.
29. Cheng C.W., Yu J.C., Huang C.S., Shieh J.C., Fu Y.P., Wang H.W., et al. Polymorphism of cytosolic serine hydroxymethyltransferase, estrogen and breast cancer risk among Chinese women in Taiwan. Breast Cancer Res Treat 2008, 111:145-155.
30. Yu C.P., Wu M.H., Chou Y.C., Yang T., You S.L., Chen C.J., et al. Breast cancer risk associated with multigenotypic polymorphisms in folate-metabolizing genes: a nested case-control study in Taiwan. Anticancer Res 2007, 27:1727-1732.
31. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995, 10:111-113.
32. Andreassi M.G., Botto N., Cocci F., Battaglia D., Antonioli E., Masetti S., et al. Methylenetetrahydrofolate reductase gene C677T polymorphism, homocysteine, vitamin B12, and DNA damage in coronary artery disease. Hum Genet 2003, 112:171-177.
33. Rozen R. Genetic modulation of homocysteinemia. Semin Thromb Hemost 2000, 26:255-261.
34. Chen J., Stampfer M.J., Ma J., Selhub J., Malinow M.R., Hennekens C.H., et al. Influence of a methionine synthase (D919G) polymorphism on plasma homocysteine and folate levels and relation to risk of myocardial infarction. Atherosclerosis 2001, 154:667-672.
35. Harmon D.L., Shields D.C., Woodside J.V., McMaster D., Yarnell J.W., Young I.S., et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol 1999, 17:298-309.
36. Dorszewska J., Florczak J., Rozycka A., Kempisty B., Jaroszewska-Kolecka J., Chojnacka K., et al. Oxidative DNA damage and level of thiols as related to polymorphisms of MTHFR, MTR, MTHFD1 in Alzheimer's and Parkinson's diseases. Acta Neurobiol Exp (Wars) 2007, 67:113-129.
37. Scazzone C., Acuto S., Guglielmini E., Campisi G., Bono A. Methionine synthase reductase (MTRR) A66G polymorphism is not related to plasma homocysteine concentration and the risk for vascular disease. Exp Mol Pathol 2009, 86:131-133.
38. Szvetko A.L., Fowdar J., Nelson J., Colson N., Tajouri L., Csurhes P.A., et al. No association between MTHFR A1298C and MTRR A66G polymorphisms, and MS in an Australian cohort. J Neurol Sci 2007, 252:49-52.
39. Terruzzi I., Senesi P., Fermo I., Lattuada G., Luzi L. Are genetic variants of the methyl group metabolism enzymes risk factors predisposing to obesity?. J Endocrinol Invest 2007, 30:747-753.
40. Barbosa P.R., Stabler S.P., Machado A.L., Braga R.C., Hirata R.D., Hirata M.H., et al. Association between decreased vitamin levels and MTHFR, MTR and MTRR gene polymorphisms as determinants for elevated total homocysteine concentrations in pregnant women. Eur J Clin Nutr 2008, 62:1010-1021.
41. de Lau L.M., Koudstaal P.J., van Meurs J.B., Uitterlinden A.G., Hofman A., Breteler M.M. Methylenetetrahydrofolate reductase C677T genotype and PD. Ann Neurol 2005, 57:927-930.
42. Vinukonda G., Shaik Mohammad N., Md Nurul Jain J., Prasad Chintakindi K., Rama Devi Akella R. Genetic and environmental influences on total plasma homocysteine and coronary artery disease (CAD) risk among South Indians. Clin Chim Acta 2009, 405:127-131.
43. Finkelstein J.D. Methionine metabolism in mammals. J Nutr Biochem 1990, 1:228-237.
44. Fredriksen A., Meyer K., Ueland P.M., Vollset S.E., Grotmol T., Schneede J. Large-scale population-based metabolic phenotyping of thirteen genetic polymorphisms related to one-carbon metabolism. Hum Mutat 2007, 28:856-865.
45. Gaughan D.J., Kluijtmans L.A., Barbaux S., McMaster D., Young I.S., Yarnell J.W., et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis 2001, 157:451-456.
46. Gueant-Rodriguez R.M., Juilliere Y., Candito M., Adjalla C.E., Gibelin P., Herbeth B., et al. Association of MTRRA66G polymorphism (but not of MTHFR C677T and A1298C, MTRA2756G, TCN C776G) with homocysteine and coronary artery disease in the French population. Thromb Haemost 2005, 94:510-515.